Radiation and immunotherapy for lung cancer that didn't respond enough
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial studies a new radiation technique called SFRT combined with chemoimmunotherapy for people with stage III lung cancer that did not respond well enough to the first round of treatment. The goal is to see if this combination can make the cancer shrink more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have locally advanced (stage III) non-small cell lung cancer that was not surgically removed.
- You must have already received at least 2 cycles of chemoimmunotherapy (chemotherapy plus an immunotherapy drug) as initial treatment.
- Your cancer must not have shrunken enough after that initial treatment (called a suboptimal response).
- You must be 18 years or older and physically able to perform daily activities (ECOG score of 0 or 1).
- Your blood counts, liver, and kidney function must be adequate to safely receive radiation and further therapy.
- You must not have had radiation to the chest before, and you must not have active autoimmune conditions or severe side effects from previous immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests whether adding a special radiotherapy technique called lattice radiotherapy to your usual cancer treatment can help control NSCLC that has started to grow in a few new spots. If you have up to 5 growing tumors and at least one measures 4.5 cm or larger, this study might be an option.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Hear when a new Thoracic Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.